270 related articles for article (PubMed ID: 37106746)
1. COVID-19 in Adult Patients with Hematological Malignancies-Lessons Learned after Three Years of Pandemic.
Hus I; Szymczyk A; Mańko J; Drozd-Sokołowska J
Biology (Basel); 2023 Apr; 12(4):. PubMed ID: 37106746
[TBL] [Abstract][Full Text] [Related]
2. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
Amanpour S
Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
[TBL] [Abstract][Full Text] [Related]
3. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
[TBL] [Abstract][Full Text] [Related]
4. A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies.
Noori M; Azizi S; Abbasi Varaki F; Nejadghaderi SA; Bashash D
Int Immunopharmacol; 2022 Sep; 110():109046. PubMed ID: 35843148
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of vaccination against SARS-CoV-2 and the need for alternative preventative approaches in immunocompromised individuals: a narrative review of systematic reviews.
Tan TT; Ng HJ; Young B; Khan BA; Shetty V; Azmi N; Clissold S
Expert Rev Vaccines; 2023; 22(1):341-365. PubMed ID: 36920116
[TBL] [Abstract][Full Text] [Related]
6. Could SARS-CoV-1 Vaccines in the Pipeline Have Contributed to Fighting the COVID-19 Pandemic? Lessons for the Next Coronavirus Plague.
López D; García-Peydró M
Biomedicines; 2023 Dec; 12(1):. PubMed ID: 38255169
[TBL] [Abstract][Full Text] [Related]
7. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
[TBL] [Abstract][Full Text] [Related]
8. Coronavirus disease 2019 (COVID-19) pandemic and pregnancy.
Dashraath P; Wong JLJ; Lim MXK; Lim LM; Li S; Biswas A; Choolani M; Mattar C; Su LL
Am J Obstet Gynecol; 2020 Jun; 222(6):521-531. PubMed ID: 32217113
[TBL] [Abstract][Full Text] [Related]
9. Hematological Questions in Personalized Management of COVID-19 Vaccination.
Wu T; Li J; Hu Y; Tang LV
J Pers Med; 2023 Jan; 13(2):. PubMed ID: 36836493
[TBL] [Abstract][Full Text] [Related]
10. Chronic Lymphocytic Leukemia in the SARS-CoV-2 Pandemic.
Arellano-Llamas AA; Vela-Ojeda J; Hernandez-Caballero A
Curr Oncol Rep; 2022 Feb; 24(2):209-213. PubMed ID: 35061199
[TBL] [Abstract][Full Text] [Related]
11. Recent Antiviral Treatment and Vaccination Strategies Against SARS-CoV-2.
Bormann M; van de Sand L; Witzke O; Krawczyk A
Klin Monbl Augenheilkd; 2021 May; 238(5):569-578. PubMed ID: 34020485
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of serological response to anti-SARS-CoV-2 mRNA vaccination in hematological patients.
Pascale SP; Nuccorini R; Pierri T; Di Mare R; Fabio L; Lerose E; Merlino MA; Schiavo P; Amendola A; Brucoli G; Caputo MD; Chitarrelli I; Cimminiello M; Coluzzi S; Filardi NB; Matturro A; Vertone D; Poggiaspalla M; Malaspina F; Musuraca G; Coralluzzo G; Mannarella C; Musto C; Bellettieri AP; Martinelli G; Cerchione C; Pizzuti M
Front Immunol; 2022; 13():892331. PubMed ID: 36003404
[TBL] [Abstract][Full Text] [Related]
13. A randomized multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts (MeCOVID Trial): A structured summary of a study protocol for a randomised controlled trial.
García IG; Rodriguez-Rubio M; Mariblanca AR; de Soto LM; García LD; Villatoro JM; Parada JQ; Meseguer ES; Rosales MJ; González J; Arribas JR; Carcas AJ; de la Oliva P; Borobia AM
Trials; 2020 Jun; 21(1):466. PubMed ID: 32493475
[TBL] [Abstract][Full Text] [Related]
14. The management of hematologic malignancies during the COVID-19 pandemic.
Hus I; Salomon-Perzyński A; Tomasiewicz K; Robak T
Expert Opin Pharmacother; 2021 Apr; 22(5):565-582. PubMed ID: 33342308
[No Abstract] [Full Text] [Related]
15. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 and HIV: Epidemiology, Treatment, and Lessons Learned from HIV.
Castel AD; Wilbourn B; Magnus M; Greenberg AE
AIDS Rev; 2020; 22(3):133-142. PubMed ID: 33118529
[TBL] [Abstract][Full Text] [Related]
17. EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients.
Cornberg M; Buti M; Eberhardt CS; Grossi PA; Shouval D
J Hepatol; 2021 Apr; 74(4):944-951. PubMed ID: 33563499
[TBL] [Abstract][Full Text] [Related]
18. Clinical trials and the COVID-19 pandemic.
Retsas S
Hell J Nucl Med; 2020; 23(1):4-5. PubMed ID: 32361715
[TBL] [Abstract][Full Text] [Related]
19. Vaccination for SARS-CoV-2 in Hematological Patients.
Riccardi N; Falcone M; Yahav D
Acta Haematol; 2022; 145(3):257-266. PubMed ID: 35220303
[TBL] [Abstract][Full Text] [Related]
20. Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination.
Zheng C; Kar I; Chen CK; Sau C; Woodson S; Serra A; Abboud H
CNS Drugs; 2020 Sep; 34(9):879-896. PubMed ID: 32780300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
